DOPAMINE PATHWAY, VBASAL GANGLIA, BASAL STRIATA, HIPPOCAMPUS

DOPAMINE PATHWAY, VBASAL GANGLIA, BASAL STRIATA, HIPPOCAMPUS

130 bookmarks
Custom sorting
Knowing the Enemy Is Halfway towards Victory: A Scoping Review on Opioid-Induced Hyperalgesia - PubMed
Knowing the Enemy Is Halfway towards Victory: A Scoping Review on Opioid-Induced Hyperalgesia - PubMed
Opioid-induced hyperalgesia (OIH) is a paradoxical effect of opioids that is not consensually recognized in clinical settings. We conducted a revision of clinical and preclinical studies and discuss them side by side to provide an updated and renewed view on OIH. We critically analyze data on the hu …
·pubmed.ncbi.nlm.nih.gov·
Knowing the Enemy Is Halfway towards Victory: A Scoping Review on Opioid-Induced Hyperalgesia - PubMed
Midazolam, methamphetamine, morphine and nicotine intake in high-drinking-in-the-dark mice - PubMed
Midazolam, methamphetamine, morphine and nicotine intake in high-drinking-in-the-dark mice - PubMed
The high-drinking-in-the-dark (HDID) lines of mice were selectively bred for achieving high blood alcohol levels in the drinking-in-the-dark (DID) task and have served as a unique genetic risk model for binge-like alcohol intake. However, little is known about their willingness to consume other addi …
·pubmed.ncbi.nlm.nih.gov·
Midazolam, methamphetamine, morphine and nicotine intake in high-drinking-in-the-dark mice - PubMed
Medications for management of opioid use disorder - PubMed
Medications for management of opioid use disorder - PubMed
Buprenorphine has become the medication of choice for many patients with OUD, but its use is limited by the low number of physicians certified to prescribe the agent. Other agents studied for treatment of OUD include methadone and naltrexone.
·pubmed.ncbi.nlm.nih.gov·
Medications for management of opioid use disorder - PubMed
Supervised dosing with a long-acting opioid medication in the management of opioid dependence - PubMed
Supervised dosing with a long-acting opioid medication in the management of opioid dependence - PubMed
Take-home medication strategies are attractive to treatment services due to lower costs, and place less restrictions on clients, but it is unknown whether they may be associated with increased risk of diversion and unsanctioned use of medication. There is uncertainty about the effects of supervised …
·pubmed.ncbi.nlm.nih.gov·
Supervised dosing with a long-acting opioid medication in the management of opioid dependence - PubMed
Iteration is not solving the opioid crisis, it's time for transformation - PubMed
Iteration is not solving the opioid crisis, it's time for transformation - PubMed
Opioid use disorder (OUD) produces exceedingly high rates of morbidity and mortality in the United States and throughout the world. Almost 90% of persons qualifying for treatment do not enter treatment and 72% of those who initiate treatment leave within 60 days. This Perspective posits that over th …
·pubmed.ncbi.nlm.nih.gov·
Iteration is not solving the opioid crisis, it's time for transformation - PubMed
"Just fighting for my life to stay alive": a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories - PubMed
"Just fighting for my life to stay alive": a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories - PubMed
In this study that qualitatively examines the experiences of people with incarceration histories and OUD enrolled in methadone treatment, we found that participants faced many barriers to community re-entry, particularly surrounding basic resources and treatment engagement. Participants reported fee …
·pubmed.ncbi.nlm.nih.gov·
"Just fighting for my life to stay alive": a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories - PubMed
Telehealth for opioid use disorder: retention as a function of demographics and rurality - PubMed
Telehealth for opioid use disorder: retention as a function of demographics and rurality - PubMed
Background: Despite lifesaving medications such as buprenorphine and methadone, the majority of individuals with opioid use disorder (OUD) face access barriers to evidence-based treatment. COVID-19 era regulatory reforms have shown that telehealth can improve access to care, although disparit …
·pubmed.ncbi.nlm.nih.gov·
Telehealth for opioid use disorder: retention as a function of demographics and rurality - PubMed
'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue - PubMed
'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue - PubMed
Depot buprenorphine remains a promising treatment for OUD and offers potential to improve treatment adherence. Instances of restricted OAT choice and consumer concerns regarding a lack of agency must be addressed in order to enhance therapeutic relationships. Clinicians and other healthcare workers …
·pubmed.ncbi.nlm.nih.gov·
'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue - PubMed
Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study - PubMed
Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study - PubMed
The current study did not demonstrate a statistically significant effect of cannabis use on outcomes of interest in the context of a pragmatic randomized-controlled trial. These findings replicated previous results reporting no effect of cannabis use on opioid-related outcomes.
·pubmed.ncbi.nlm.nih.gov·
Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study - PubMed
Integrating cognitive bias modification for pain and opioid cues into medication for opioid use disorder clinical care: Feasibility, acceptability, and preliminary results - PubMed
Integrating cognitive bias modification for pain and opioid cues into medication for opioid use disorder clinical care: Feasibility, acceptability, and preliminary results - PubMed
The current study supports integrating brief, computer-based tasks designed to reduce AB into mOUD clinical care. The preliminary results suggest that TLBS outcomes may be more sensitive to capture changes in AB; however, larger studies are required.
·pubmed.ncbi.nlm.nih.gov·
Integrating cognitive bias modification for pain and opioid cues into medication for opioid use disorder clinical care: Feasibility, acceptability, and preliminary results - PubMed
Substance use disorder bridge clinics: models, evidence, and future directions - PubMed
Substance use disorder bridge clinics: models, evidence, and future directions - PubMed
Bridge clinics represent a critical innovation, offering on-demand access to MOUD and other services. Evaluating the effectiveness of bridge clinics in linking patients to long-term care settings remains an important research priority; however, available data show promising rates of treatment initia …
·pubmed.ncbi.nlm.nih.gov·
Substance use disorder bridge clinics: models, evidence, and future directions - PubMed
Duration of medication for opioid use disorder during pregnancy and postpartum by race/ethnicity: Results from 6 state Medicaid programs - PubMed
Duration of medication for opioid use disorder during pregnancy and postpartum by race/ethnicity: Results from 6 state Medicaid programs - PubMed
There are stark racial/ethnic differences in MOUD during pregnancy and the first year postpartum. Reducing these inequities is critical to improving health outcomes among pregnant and postpartum women with OUD.
·pubmed.ncbi.nlm.nih.gov·
Duration of medication for opioid use disorder during pregnancy and postpartum by race/ethnicity: Results from 6 state Medicaid programs - PubMed
Prevalence of Buprenorphine Providers Requiring Cash Payment From Insured Women Seeking Opioid Use Disorder Treatment - PubMed
Prevalence of Buprenorphine Providers Requiring Cash Payment From Insured Women Seeking Opioid Use Disorder Treatment - PubMed
State-to-state variation was the most striking pattern in our field experiment data. The wide variation suggests that women of reproductive age with OUD in certain states face even greater challenges to treatment access than perhaps previously thought; however, it also reveals that some states have …
·pubmed.ncbi.nlm.nih.gov·
Prevalence of Buprenorphine Providers Requiring Cash Payment From Insured Women Seeking Opioid Use Disorder Treatment - PubMed
Biopsychosocial contexts of timely and adequate prenatal care utilization among women with criminal legal involvement and opioid use disorder - PubMed
Biopsychosocial contexts of timely and adequate prenatal care utilization among women with criminal legal involvement and opioid use disorder - PubMed
While not causal, results suggest that timely and adequate prenatal care among women with CL-OUD may be supported by OUD treatment, comorbid indications for care, stable access to social resources, and maintained residence in the community (i.e., community-based alternatives to incarceration).
·pubmed.ncbi.nlm.nih.gov·
Biopsychosocial contexts of timely and adequate prenatal care utilization among women with criminal legal involvement and opioid use disorder - PubMed
Augmenting project ECHO for opioid use disorder with data-informed quality improvement - PubMed
Augmenting project ECHO for opioid use disorder with data-informed quality improvement - PubMed
Results suggest that training clinics to monitor their performance and base QI initiatives on data has potential to impact clinical best practice. While data collection was inconsistent, clinics completed several data-informed QI initiatives, indicating that smaller scale data collection might be mo …
·pubmed.ncbi.nlm.nih.gov·
Augmenting project ECHO for opioid use disorder with data-informed quality improvement - PubMed
The Impact of Individual Counseling on Treatment for Opioid Use - PubMed
The Impact of Individual Counseling on Treatment for Opioid Use - PubMed
In 2018, more than 67,000 people died because of drug overdoses, and of that number, approximately 69.5% involved an opioid, making it a leading cause of death in the United States. Additionally concerning is that 40 states have reported increased overdose deaths and opioid-related deaths since the …
·pubmed.ncbi.nlm.nih.gov·
The Impact of Individual Counseling on Treatment for Opioid Use - PubMed
Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings - PubMed
Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings - PubMed
Efforts are needed to support clinicians outside of SUD specialty settings in providing buprenorphine care to patients with co-occurring substance use. These could include clearer guidelines and policies, more specific training, and increased care integration or cross-disciplinary collaboration. Sim …
·pubmed.ncbi.nlm.nih.gov·
Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings - PubMed
"It's Like Your Whole Body Hates You": Experiences of Withdrawal, Distress, and Barriers to Relief Among Adults Receiving Methadone for Opioid Use Disorder - PubMed
"It's Like Your Whole Body Hates You": Experiences of Withdrawal, Distress, and Barriers to Relief Among Adults Receiving Methadone for Opioid Use Disorder - PubMed
A qualitative descriptive study was conducted concurrent with a larger study investigating the effects of hyperbaric oxygen treatment on withdrawal symptoms for adults receiving daily methadone for opioid use disorder. The aims of this study were to (a) evaluate the perceptions of withdrawal symptom …
·pubmed.ncbi.nlm.nih.gov·
"It's Like Your Whole Body Hates You": Experiences of Withdrawal, Distress, and Barriers to Relief Among Adults Receiving Methadone for Opioid Use Disorder - PubMed
Methadone alters transcriptional programs associated with synapse formation in human cortical organoids - PubMed
Methadone alters transcriptional programs associated with synapse formation in human cortical organoids - PubMed
Opioid use disorder (OUD) among pregnant women has become an epidemic in the United States. Pharmacological interventions for maternal OUD most commonly involve methadone, a synthetic opioid analgesic that attenuates withdrawal symptoms and behaviors linked with drug addiction. However, evidence of …
·pubmed.ncbi.nlm.nih.gov·
Methadone alters transcriptional programs associated with synapse formation in human cortical organoids - PubMed
More than just 'free heroin': Caring whilst navigating constraint in the delivery of diamorphine assisted treatment - PubMed
More than just 'free heroin': Caring whilst navigating constraint in the delivery of diamorphine assisted treatment - PubMed
Despite some operational complexities, health care providers viewed HAT as an effective method of engaging a high risk population with drug treatment services, with holistic benefits for clients over and above the treatment of opioid dependency. Findings will inform advocacy and innovation for futur …
·pubmed.ncbi.nlm.nih.gov·
More than just 'free heroin': Caring whilst navigating constraint in the delivery of diamorphine assisted treatment - PubMed
Drug use, health and social outcomes of hard-to-treat heroin addicts receiving supervised injectable opiate treatment: secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT) - PubMed
Drug use, health and social outcomes of hard-to-treat heroin addicts receiving supervised injectable opiate treatment: secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT) - PubMed
Supervised injectable heroin treatment and supervised injectable methadone treatment showed no clearly identified benefit over optimized oral methadone in terms of wider drug use, crime, physical and mental health within a 6-month period, despite reducing street heroin use to a greater extent. Howev …
·pubmed.ncbi.nlm.nih.gov·
Drug use, health and social outcomes of hard-to-treat heroin addicts receiving supervised injectable opiate treatment: secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT) - PubMed
'This is hardcore': a qualitative study exploring service users' experiences of Heroin-Assisted Treatment (HAT) in Middlesbrough, England - PubMed
'This is hardcore': a qualitative study exploring service users' experiences of Heroin-Assisted Treatment (HAT) in Middlesbrough, England - PubMed
The Middlesbrough HAT programme provided benefits to a high-risk population of opioid dependent people who were unable or disinclined to participate in conventional opioid substitution treatments. The findings in this paper highlight the potential for service modifications to further enhance engagem …
·pubmed.ncbi.nlm.nih.gov·
'This is hardcore': a qualitative study exploring service users' experiences of Heroin-Assisted Treatment (HAT) in Middlesbrough, England - PubMed
Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone? - PubMed
Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone? - PubMed
Individual patient characteristics and preferences should be taken into consideration when choosing a first-line opioid agonist treatment. For patients at high risk of dropout (such as adolescents and socially unstable patients), treatment retention should take precedence over other clinical conside …
·pubmed.ncbi.nlm.nih.gov·
Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone? - PubMed
Sensitivity to change of generic preference-based instruments (EQ-5D-3L, EQ-5D-5L, and HUI3) in the context of treatment for people with prescription-type opioid use disorder in Canada - PubMed
Sensitivity to change of generic preference-based instruments (EQ-5D-3L, EQ-5D-5L, and HUI3) in the context of treatment for people with prescription-type opioid use disorder in Canada - PubMed
Negligible differences were observed between the EQ-5D-3L, EQ-5D-5L, and HUI3 regarding the ability to measure change. The prevalence of data quality violations-which differed by ethnicity-requires further investigation.
·pubmed.ncbi.nlm.nih.gov·
Sensitivity to change of generic preference-based instruments (EQ-5D-3L, EQ-5D-5L, and HUI3) in the context of treatment for people with prescription-type opioid use disorder in Canada - PubMed